Low-dose lung radiotherapy for COVID-19 lung disease: a preclinical efficacy study in a bleomycin model of pneumonitis.

Mark R Jackson (DPhil), Katrina Stevenson (MSc), Sandeep K. Chahal (MRes), Emer Curley (MSc), George E Finney (MSc), Rodrigo Gutierrez-Quintana (MVM), Evarest Onwubiko (MSc), Angie Rupp (DipECVP), Karen Strathdee (BSc), Karin Williams (PhD), Megan KL MacLeod (PhD), Charles McSharry (PhD), Anthony J Chalmers (MD PhD)

PII: S0360-3016(21)02720-6
DOI: https://doi.org/10.1016/j.ijrobp.2021.08.029
Reference: ROB 27245

To appear in: International Journal of Radiation Oncology, Biology, Physics

Received date: 10 March 2021
Revised date: 5 August 2021
Accepted date: 24 August 2021

Please cite this article as: Mark R Jackson (DPhil), Katrina Stevenson (MSc), Sandeep K. Chahal (MRes), Emer Curley (MSc), George E Finney (MSc), Rodrigo Gutierrez-Quintana (MVM), Evarest Onwubiko (MSc), Angie Rupp (DipECVP), Karen Strathdee (BSc), Karin Williams (PhD), Megan KL MacLeod (PhD), Charles McSharry (PhD), Anthony J Chalmers (MD PhD), Low-dose lung radiotherapy for COVID-19 lung disease: a preclinical efficacy study in a bleomycin model of pneumonitis., International Journal of Radiation Oncology, Biology, Physics (2021), doi: https://doi.org/10.1016/j.ijrobp.2021.08.029

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Published by Elsevier Inc.
Low-dose lung radiotherapy for COVID-19 lung disease: a preclinical efficacy study in a bleomycin model of pneumonitis.

[Running title]
LDLR in a bleomycin model of pneumonitis.

[Author Names]
Mark R Jackson (DPhil)\(^1\), Katrina Stevenson (MSc)\(^1\), Sandeep K. Chahal (MRes)\(^1\), Emer Curley (MSc)\(^4\), George E Finney (MSc)\(^2\), Rodrigo Gutierrez-Quintana (MVM)\(^1,3\), Evarest Onwubiko (MSc)\(^4\), Angie Rupp (DipECVP)\(^3\), Karen Strathdee (BSc)\(^1\), Karin Williams (PhD)\(^1\), Megan KL MacLeod (PhD)\(^2\), Charles McSharry (PhD)\(^2\), Anthony J Chalmers (MD PhD)\(^1\)

[Author Institutions]
1Institute of Cancer Sciences, University of Glasgow, UK
2Institute of Infection, Immunity and Inflammation, University of Glasgow, UK
3School of Veterinary Medicine, University of Glasgow, UK
4Cancer Research UK Beatson Institute, Glasgow, UK

[Corresponding Author Name & Email Address]
Anthony J Chalmers
anthony.chalmers@glasgow.ac.uk

[Author Responsible for Statistical Analysis Name & Email Address]
Mark R Jackson
mark.jackson.2@glasgow.ac.uk

[Conflict of Interest Statement for All Authors]
Conflict of Interest: None
[Funding Statement]
This study was made possible by the following funding sources: AC: Medical Research Council Research Grant (MRR0094731); AC, KStevenson: Cancer Research UK Radiation Research Centre of Excellence (C16583/A28803); KStrathdee: Cancer Research UK Clinician Scientist Fellowship (Ross Carruthers, C52808/A23920); MMacL: Wellcome Trust [210703/Z/18/Z]; CMcS: BPF Medical Research Trust (SCO1318).

[Data Availability Statement for this Work]
Research data are stored in an institutional repository and will be shared upon request to the corresponding author.

[Acknowledgements]
The authors gratefully acknowledge the following people for their contributions to this research: University of Glasgow Flow Core Facility; Colin Nixon (CRUK Beatson Institute Core Histology Service); David Lewis (CRUK Beatson Institute) for CT quantification advice; Lesley Gilmour (University of Glasgow) for in vivo experimental design advice; Karen Blyth (CRUK Beatson Institute); Ashley Tatum for project management advice.

Abstract
Purpose
Low-dose whole lung radiotherapy (LDLR) has been proposed as a treatment for patients with acute respiratory distress syndrome associated with SARS-CoV-2 infection and clinical trials are underway. There is an urgent need for preclinical evidence to justify this approach and inform dose, scheduling and mechanisms of action.

Materials and methods

Female C57BL/6 mice were treated with intranasal bleomycin sulphate (7.5 or 11.25 units/kg, day 0), then exposed to whole lung radiation therapy (0.5, 1.0, 1.5 Gy or sham, day 3). Bodyweight was measured daily and lung tissue harvested for histology and flow cytometry on day 10. Computed tomography (CT) lung imaging was performed pre-radiation (day 3) and pre-endpoint (day 10).

Results

Bleomycin caused pneumonitis of variable severity which correlated with weight loss. LDLR at 1.0 Gy was associated with a significant increase in the proportion of mice recovering to 98% of initial bodyweight and a proportion of these mice exhibited less severe histopathological lung changes. Mice experiencing moderate initial weight loss were more likely to respond to LDLR than those experiencing severe initial weight loss. Additionally, LDLR (1.0 Gy) significantly reduced bleomycin-induced increases in interstitial macrophages, CD103+ dendritic cells and neutrophil-DC hybrids. Overall, bleomycin-treated mice exhibited significantly higher percentages of non-aerated lung in left than right lungs and LDLR (1.0 Gy) limited further reductions in aerated lung volume in right but not left lungs. LDLR at 0.5 and 1.5 Gy did not
improve bodyweight, flow cytometric or radiological readouts of bleomycin-induced pneumonitis.

Conclusions

Our data support the concept that LDLR can ameliorate acute inflammatory lung injury, identify 1.0 Gy as the most effective dose and provide evidence that it is more effective in the context of moderate than severe pneumonitis. Mechanistically, LDLR at 1.0 Gy significantly suppressed bleomycin-induced accumulation of pulmonary interstitial macrophages, CD103+ dendritic cells and neutrophil-DC hybrids.

Introduction

To date (August 2021), infection with the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has been associated with more than 4,250,000 deaths globally (1). Infection with SARS-CoV-2 can cause a syndrome termed COVID-19, the severity of which varies widely. A small proportion of patients develop severe pneumonia and acute respiratory distress syndrome (ARDS) (2) characterised by pathological inflammation, the severity of which correlates with mortality (3). The histopathological features and systemic complications are characteristic of ARDS and cytokine release syndrome (CRS) (4). Pathological features include infiltration of alveoli by macrophages, lymphocytes and neutrophils, and high levels of pro-inflammatory cytokines such as interleukins-6 and 1β, interferon gamma and tumour necrosis factor (5,6).
There are very few effective treatments for COVID-19 lung disease. The RECOVERY trial (UK) showed that dexamethasone treatment was associated with a reduction in 28-day mortality compared with standard of care among hospitalised patients who required ventilatory support (Relative risk [RR] 0.65) or oxygenation (RR 0.80) (7). More recently, the REMAP-CAP trial reported improvements in survival and time to recovery following dual therapy with tocilizumab and sarilumab (unpublished data), and the anti-inflammatory agent colchicine has been reported to reduce hospitalisation and mortality in COVID-19 patients with at least one risk factor for complications (8). While some of these studies await peer review, the early clinical data support the concept that acute inflammation is the key pathological process in COVID-19 lung disease, and indicate that broad spectrum immunosuppressive therapies may be of therapeutic value.

Low-dose whole lung radiotherapy (LDLR; radiation doses ≤1.5 Gy) was used extensively as a treatment for pneumonias of various aetiologies in the pre-antibiotic era (9). In various preclinical models of inflammation, LDLR has been shown to induce anti-inflammatory cytokine production, reduce leucocyte-endothelial adhesion, and repolarise myeloid and lymphoid cells towards immune-suppressive phenotypes (10). Recent preclinical studies have generated preliminary data to indicate that LDLR (0.5-1.0 Gy) reduces pneumonitis in lipopolysaccharide (LPS) and influenza virus mouse models (11). These diverse but limited bodies of evidence have underpinned early phase clinical trials of LDLR for acutely unwell COVID-19 patients in several countries including the USA, India and Spain. The safety of the intervention is supported by preliminary results from phase I trials (12,13), in which early signals of efficacy were reported including in elderly patients with severe COVID-19 lung disease, most of whom had multiple comorbidities (12). Very
recently, however, the first randomised clinical data to be published \((n=22)\) showed no benefit of 1.0 Gy whole lung radiotherapy over sham irradiation in ventilation-dependent patients with severe COVID-19 pneumonia (14).

This therapeutic approach has generated intense controversy (15-18). While expressing diverse opinions, the vast majority of stakeholders have emphasised the urgent need for high quality preclinical data to (i) justify (or not) the commencement of clinical studies, (ii) elucidate mechanisms of efficacy and (iii) inform decisions on radiation dose, scheduling and target volume (19). To address this need, we undertook preclinical studies using a mouse model of bleomycin-induced pneumonitis. Many pathophysiological changes of COVID-19 lung disease (epithelial cytopathy, endotheliitis, inflammatory infiltrates, surfactant loss) are reproduced in the pneumonitis induced by inhaled bleomycin (20,21). Indeed, single cell sequencing studies of mouse bleomycin (22) and COVID-19 (23,24) pneumonitis have shown pathogenic SPP1\(^{pos}\) macrophage orthologues expressing key inflammatory mediators to be prominent in both conditions, along with profoundly reduced expression of anticoagulant and anti-apoptotic protein S in alveolar macrophages. Exogenous protein S is protective of bleomycin pneumonitis (25) and has been proposed as a potential treatment for COVID-19 (26).

To test the hypothesis that LDLR would reduce the severity of bleomycin-induced acute lung injury by exerting suppressive effects on cellular and molecular components of the inflammatory response, we measured the effects of 0.5, 1.0 and 1.5 Gy whole lung irradiation on bodyweight (primary endpoint); pulmonary cytology and histology, and lung computed tomography (CT) appearances (secondary endpoints). Our data show that 1.0 Gy LDLR enhances recovery in a proportion of bleomycin-treated mice, with corresponding improvements in lung histopathology
and imaging parameters and modulation of specific immune cell populations. Effects were more marked in mice with moderate rather than severe pneumonitis.

Materials and Methods

Reagents

All reagents were purchased from Biolegend unless otherwise stated. Bleomycin sulphate was obtained from European Pharmacopeia EDQM, Council of Europe, France. Intranasal bleomycin dose was 11.25 units/kg except in the initial pilot study, when 7.5 units/kg was also used.

Experimental pneumonitis

Bleomycin generates a well-established murine model of pneumonitis (21) with a dynamic pathology similar to that of COVID-19. Female, 11-13 week old C57BL/6 mice (Charles River Laboratories) were administered one intranasal 40 µL dose of bleomycin sulphate (7.5 or 11.25 units/kg) or phosphate buffered saline (PBS) vehicle control under light isoflurane anaesthesia. Mice were maintained in a pathogen-free facility, provided with additional high calorie, soft diet to ease feeding, and monitored daily for wellbeing and change in bodyweight. Those demonstrating signs of illness such as lethargy, isolation, reduced mobility, altered respiration, or ≥25% weight-loss were humanely culled. The experimental design optimised mice numbers to comply with the principles of Replacement, Reduction and Refinement for humane animal research. Procedures were governed by the Animals Scientific Procedures Act 1986 and approved by Home Office licence PP6245051.

Low-dose lung radiotherapy (LDLR)
Bleomycin-treated mice exhibiting a day 3 relative bodyweight area-under-the-curve (AUC) $\leq 2.92$ were randomised to receive LDLR or sham irradiation. Anaesthetised mice were irradiated with low-dose whole lung radiotherapy (0.5, 1.0, 1.5 Gray or sham) on day 3, using the Small Animal Radiation Research Platform (SARRP) developed by XStrahl. A 220 kVp, 13 mA X-ray beam was used with a dose rate of approximately 280 cGy min$^{-1}$ at the chosen aperture size. Treatment was delivered with anterior and posterior parallel opposed fields. The broad focal spot (5.5 mm) was used and the SARRP's motorised variable collimator set to an aperture size of 20 x 20 mm to ensure full coverage of both lungs. Mice were culled on day 10 and lung tissue harvested for experimental endpoint analysis as described below.

**CT assessment of lung changes**

Lung changes were measured using the SARRP’s in-built cone-beam CT (CBCT) function to image anaesthetised mice on days 3 (pre-irradiation) and 10 (experimental endpoint). Images were reconstructed using the FDK (Feldkamp, Davis and Kress) CBCT reconstruction algorithm from 1440 projections taken at 60 kVp and 0.8 mA using the fine focal spot (1 mm). The absorbed dose associated with each CBCT was calculated to be approximately 4.8 cGy. For quantification of aerated lung volumes, Hounsfield unit (HU) clinical ranges were used: poorly aerated lung defined as -500 to -100 HU and normo-aerated defined as -900 to -500 HU. Images were analysed using the Lung CT analyzer module from the 3D Slicer software extension SlicerCIP (27,28). Additional detail is provided in the supplementary information.

**Tissue collection**
Mice were culled by terminal intraperitoneal injection of 100 μL sodium pentobarbital (200 mg/ml) and cardiac exsanguination. The trachea was exposed, a small transverse opening cut between cartilage rings and a ligature tied loosely distal to the cut. The protruding 0.5 cm tip of a cannula sheath around a 23G syringe needle was inserted into the opening and the ligature tightened. The lungs were lavaged twice with 0.8 mL PBS and then perfused via the right ventricle with cold PBS until they blanched, after which lungs and heart were removed en bloc. The left lobe of the lung was excised, submerged in 4% neutral buffered formalin fixative for 24hr and processed for histology while the right lung lobes were processed for cytology.

**Lung histology**

Serial 4 μm sections of the left lobe were cut and stained with haematoxylin and eosin (H&E) and Masson’s trichrome and evaluated independently by a veterinary pathologist and a pulmonary immunologist both of whom were blinded to the experimental treatment. In brief, semiquantitative scoring (described in detail in supplementary information) examined the extent of interstitial mononuclear cell infiltrates, specifically interstitial (to intra-alveolar) macrophage infiltrates and perivascular/peribronchiolar lymphocyte aggregates.

**Lung tissue cytology**

Small pieces of right lung were incubated with dispase (3.2 mg/mL, Roche), collagenase P (0.4 mg/mL, Roche), and DNAse I (0.2 mg/mL, Sigma) in 2 mL RPMI at 37°C in a shaking incubator for 40 minutes. Lung pieces were transferred into a 100 mm strainer and a single cell suspension prepared and filter rinsed to transfer all cells into a 50 mL tube. Red blood cells were lysed by RBC lysis buffer (ThermoFisher) and viable cells counted. Next, cells were Fc blocked with 24G2
antibody and normal mouse serum for 10 minutes then incubated with fluorescently labelled antibodies for 20 minutes at 4°C. Antibodies are listed in Supp. Table S1. Following PBS washing, cells were incubated with viability dye (Zombie Aqua) for 20 minutes at 4°C, washed with FACS buffer (PBS with 2% FCS, 2 mM EDTA and 5 mM sodium azide), fixed with 2% paraformaldehyde for 20 minutes at 4°C and washed again with FACS buffer then stored at 4°C. Flow cytometry data were acquired on a BD Fortessa and analysed using FlowJo (version10, BD Biosciences). The gating strategy (29) is shown in Supp. Fig. S1.

**Statistical analysis**

Statistical analyses were performed in R 3.6.3 (30) using the packages “MESS” (31), “survival” (32) and “survminer” (33). Box and whiskers were plotted according to the Tukey method. Statistical tests used and group sizes are indicated for each experiment. Additional detail on use of area-under-the-curve (AUC) and recovery probability analyses is presented as supplementary information.

**Results**

Initially, pilot studies were conducted to characterise the bleomycin-induced pneumonitis model and establish optimum dosing and scheduling parameters. Using mouse bodyweight as a marker of systemic response, we observed variable responses to intranasal bleomycin (Fig. 1A), as reported in other studies. Area-under-the-curve (AUC) analysis revealed that, despite measurable weight loss at day 3 (Supp. Fig. S2), by day 10 the bodyweight of mice treated with 7.5 units/kg bleomycin was not significantly different to controls (Fig. 1B). In contrast,
administration of 11.25 units/kg induced progressive weight loss in the majority of mice, with 25% exhibiting a severe reduction that triggered humane endpoint sacrifice but 25% failing to show a demonstrable response (Fig. 1A,B). Histological assessment on day 3 revealed multifocal, small, interstitial to intra-alveolar macrophage infiltrates and appreciable but small, perivascular and peribronchiolar lymphocyte aggregates in the majority of mice (Fig. 1C). These were accompanied by a robust reduction in alveolar macrophages and an increase in interstitial macrophages measured by flow cytometry in dispersed lung tissue (Fig. 1D).

To mirror the clinical scenario, in which LDLR would only be considered in patients exhibiting moderate to severe COVID-19 lung disease, we opted to deliver LDLR three days after bleomycin treatment. Mice showing minimal weight loss at day 3 were excluded and those exhibiting a sustained drop in bodyweight (defined by day 3 AUC ≤ 2.92) were randomly allocated to receive LDLR or sham irradiation (Fig. 1E). Treatment of vehicle-only control mice with LDLR (1.0 Gy) was well tolerated with no effect on bodyweight and no detectable deviation from normal behaviour (Fig. 1F).

Despite the variability inherent to the bleomycin model, treatment with 1.0 Gy was associated with a modest increase in mean bodyweight in irradiated versus sham-irradiated mice from day 5 onwards (Fig. 2A). Bodyweight plots for individual mice (Fig. 2B) illustrate the variable response to bleomycin and identify a sub-population of irradiated mice recovering to at least 96% of baseline bodyweight. Kaplan-Meier analysis demonstrated a statistically significant increase in the proportion of irradiated mice recovering to at least 98% of initial bodyweight after day 3 (21.2%, n=33) compared with sham-irradiated mice (3.3%, n=30; p=0.0265), with recovery also occurring earlier (Fig. 2C). This definition of recovery (regaining 98% of initial weight) was used as a reference in subsequent analyses. Recovery was also
significantly increased in irradiated mice if a recovery threshold of 100% was imposed (p=0.0230) and a strong trend was observed at 96% (p=0.0776) (Supp Table S2). Of note, treatment with LDLR did not increase the likelihood of an adverse outcome, with no difference in the proportions of irradiated and sham-irradiated mice experiencing severe weight loss (Fig. 2D, Supp. Fig. S3).

To identify biomarkers predicting efficacy, we looked for correlations between the severity of the bleomycin response prior to irradiation (day 3), as indicated by bodyweight AUC, and response to LDLR. Of the mice receiving 1.0 Gy, those that went on to recover had significantly higher AUC values at day 3 than those that did not recover (Fig. 2E). This analysis also confirmed that there was no significant difference in mean pre-LDLR AUC between irradiated and sham irradiated mice, and that mice experiencing a severe initial response to bleomycin (low day 3 AUC) were more likely to go on to experience severe weight loss (humane endpoint), regardless of further treatment.

Histological assessment of mice on day 10 for macrophage infiltrates and lymphocyte aggregates demonstrated significant increases in immune infiltration of the lungs of bleomycin-treated mice compared to vehicle-treated mice (Fig. 3A,B). While no statistically significant difference in composite score was detected between irradiated and sham-irradiated groups, a subset of irradiated mice, composed predominantly of mice whose bodyweight had recovered after treatment (open symbols in Fig. 3A), exhibited lower levels of inflammatory cells. In keeping with this observation, there was a significant negative correlation between histological composite score and relative bodyweight AUC across all mice exposed to bleomycin (r=-0.42, p=0.0048; Supp. Fig. S4). Early fibrotic changes were observed (Supp. Fig. S5) but were deemed not substantial enough to be quantified with existing scoring.
systems for fibrosis, which have been created and validated for later timepoints than those under investigation in this study.

Immunocytological assessment of mouse lungs on day 10 showed that while the bleomycin-induced increase in interstitial macrophages was significantly blunted by lung irradiation (Fig. 4A), the associated reduction in alveolar macrophages was not affected (Fig. 4B). Bleomycin associated increases in CD103+ dendritic cells and neutrophil-DC hybrids (34) were also significantly attenuated in mice exposed to 1.0 Gy LDLR (Fig. 4C,D). Representative FACS plots are shown in Supp. Fig. S6. In addition to changes in cell number, bleomycin inhalation was associated with increased expression of the co-stimulatory molecule CD86 on alveolar macrophages and on neutrophil-DC hybrids, but reduced expression on CD103+ dendritic cells and interstitial macrophages (Supp. Fig. S7). Importantly, the reduction in expression of CD86 induced by bleomycin in interstitial macrophages was significantly attenuated by LDLR at 1.0 Gy. The numbers of lymphocytes in lung tissue were not significantly affected by bleomycin treatment (Supp. Fig. S8).

To enable longitudinal assessment of lung infiltration, mice underwent CT imaging of the thorax on day 3 (pre-irradiation) and day 10. As previously reported, bleomycin related changes were significantly more pronounced in the left lung (Fig. 5A,B); this is thought to be due to morphological differences between left and right main bronchi (35). Left and right lung datasets were therefore analysed separately. Consistent with evolving acute lung injury, aerated lung volume decreased between days 3 and 10 in sham irradiated mice (both lungs) and in the left lungs of irradiated mice (Fig. 5C). In contrast, no statistically significant deterioration was observed in the right lungs of irradiated subjects (Fig. 5C, right panel). Furthermore the mean decrease in right lung aerated volume was significantly less in irradiated mice than controls (-
3.8% and -11.9% respectively, Fig. 5D). Indeed 36% (n=22) of irradiated mice showed an improvement (change >0%) in right lung aeration at day 10, compared to only 5% (n=19) of controls. No effect of irradiation was observed in the left lungs. These observations are in keeping with the concept that LDLR has anti-inflammatory efficacy in the context of moderate pneumonitis, as seen in the right lungs, but not the left lungs, which exhibited more severe changes.

Finally we evaluated two additional LDLR doses (0.5 and 1.5 Gy) that are also being tested in clinical trials. Neither dose was associated with an improvement in outcome compared to sham irradiation, either in terms of mean bodyweight, likelihood of recovery or survival probability (Fig. 6A, Supp. Fig. S9). In keeping with this, these doses did not dampen the bleomycin associated lung infiltration of immune cell subsets that were previously shown to respond to 1.0 Gy (Fig. 6B). In fact, treatment with 1.5 Gy modestly but significantly exacerbated the bleomycin-induced reduction in lung alveolar macrophages. In contrast to 1.0 Gy, lung irradiation with 0.5 or 1.5 Gy failed to reduce deterioration of lung capacity as measured by CT imaging (Fig. 6C).

**Discussion**

While a substantial body of clinical and preclinical data describes the immunomodulatory effects of low doses of radiation, none of the previously published work has studied pneumonitis. In the absence of a validated small animal model of COVID-19 lung disease (36) and the urgent need for relevant preclinical data, we used the well characterised bleomycin model to undertake pragmatic studies that we hope will provide useful data for clinicians developing early phase
studies of LDLR in COVID-19 patients. The bleomycin model was selected because it exhibits many of the pathophysiological changes associated with COVID-19 lung disease, and because recent single cell sequencing studies support the existence of shared immunological mechanisms (22-24). However we recognise its limitations: immune responses to bleomycin and SARS-CoV-2 are not identical, neither within the lungs nor systemically. Furthermore, our experiments were conducted exclusively in female mice aged 11-13 weeks. There is some evidence that young mice are less responsive to bleomycin than older mice (37) and it is possible that male mice would respond differently to bleomycin, LDLR or both. Furthermore, it is well established that the risk of severe COVID-19 lung disease is much greater in older patients (38), and that males are at higher risk of poor outcomes (39). Interactions with clinical comorbidities have also been described.

Having identified bodyweight as a clinically relevant primary endpoint that correlates with the severity of bleomycin-induced pneumonitis and the associated systemic inflammatory response (40), we observed wide variation between mice in terms of rapidity and severity of weight loss, and subsequent recovery. Despite the challenges posed by this variability, our findings support the hypothesis that LDLR, delivered at a time when early histological and immunological features of lung inflammation are apparent, increases the likelihood of recovery in a subset of mice (approximately 25%). These bodyweight data are supported by histological, radiological and immunological observations which show that LDLR reduces the severity of bleomycin-induced lung changes in a proportion of mice. Subsequent analyses indicated that mice with moderate pneumonitis (measured by lower rates of weight loss) were more likely to respond to LDLR than those with severe pneumonitis. These findings were corroborated by imaging studies which showed
that LDLR reduced or even reversed the trajectory of bleomycin-induced changes in the right lungs, which were typically less severe than those in the left lungs, but had no impact on left lung imaging parameters. These observations are in keeping with recently published clinical data showing no benefit of LDLR in patients with severe COVID-19 pneumonia (14). Of note, histological improvement was also observed in a subset of irradiated mice, even though this assessment was performed exclusively on left lung tissue, which was generally more severely affected than right lung tissue.

Since the various clinical studies underway are evaluating a range of lung radiation doses from 0.35 to 1.5 Gy, we tested three different doses (0.5, 1.0 and 1.5 Gy) in an attempt to inform clinical decisions in this area. Of these, only 1.0 Gy demonstrated signs of efficacy, whereas 1.5 Gy showed some evidence of a detrimental effect. Cytological analyses suggest that the efficacy of 1.0 Gy likely associates with the fact that this was the only dose to significantly reduce immune infiltration of the lung. Our observations are largely consistent with the data recently published by Meziani and colleagues in lipopolysaccharide (LPS) and H1N1 influenza models of lung injury, although responses to 0.5 Gy were also observed in some of the histological and cytological readouts reported in that study (11).

Considering possible mechanisms, our cytological studies showed that inhaled bleomycin caused an acute loss of alveolar macrophages and concomitant accumulation of myeloid cell populations in the lung. Similarly, in influenza virus infection, numbers of lung dendritic cells increase as a consequence of more precursor cells migrating to the lung (41). While LDLR was unable to prevent loss of alveolar macrophages, it did reduce accumulation of key dendritic cell, macrophage, and neutrophil populations (Fig. 4). A plausible explanation is that LDLR suppresses the signals that attract precursor dendritic cells and/or inhibits their differentiation into
CD103+ dendritic cells. Infection or lung injury can lead to an accumulation of lung macrophages through either recruitment (42) or local proliferation in a Th2-helper environment (43). Bleomycin treatment has been shown to increase production of the chemokine CCL2 by lung cells (44,45); since migration of monocytes into inflamed lungs is dependent on CCL2/CCR2 signalling (44,45) it is reasonable to propose that LDLR might act by reducing CCL2 and/or other signals that attract monocytes into the damaged lung.

Chemokines such as MIP-2 and CXCL5 are released in the first few days after acute lung injury and, together with other factors including extracellular ATP, may play a role in initiating and sustaining accumulation of neutrophils within the lungs following bleomycin inhalation (46). While we saw no increase in classical neutrophils in bleomycin exposed lungs, we did observe accumulation of a hybrid population that expressed markers of both neutrophils (Ly6G) and dendritic cells (CD11c, MHCII). These hybrid cells are thought to differentiate from neutrophil precursors, retaining their phagocytic function while gaining the ability to present antigen to CD4 T cells (34). Inflammation induced by thioglycolate, bacterial or fungal infection leads to an increase in this hybrid population in mouse models of tissue inflammation and these cells have also been found in human tumours (47-49). Our data extend these observations to show that bleomycin also drives accumulation and differentiation of these cells, an effect that we showed to be significantly blunted by LDLR.

**Conclusions**

Our data provide preclinical evidence of efficacy of LDLR in a subset of mice with moderate lung injury induced by bleomycin, identify 1.0 Gy as the most effective
radiation dose tested, and reveal plausible immunological mechanisms. More comprehensive studies in additional models of pneumonitis and over longer observation periods are warranted to inform ongoing and future studies in COVID-19 patients.

References


9. Calabrese EJ, Dhawan G. How radiotherapy was historically used to treat pneumonia: could it be useful today? Yale J Biol Med 2013;86:555-70


31. Ekstrøm CT. MESS: Miscellaneous Esoteric Statistical Scripts. R package version 0.5.6. 2019


Figure Legends

Figure 1A
Figure 1B

![Graph showing relative weight AUC (days) against Bleomycin (units/kg) over Day 0-10.](image)

Figure 1C

![Micrographs comparing Vehicle and Bleomycin-treated tissues on Day 3.](image)
Figure 1D

Interstitial macrophages

Number of interstitial macrophages

Alveolar macrophages

Number of alveolar macrophages

Figure 1E

Thresholding

Relative weight AUC (days)

Bleomycin-treated

Relative bodyweight

Time (days)
Figure 1: Bleomycin induces a variable pneumonitis in young adult, female C57BL/6 mice. (A) Relative mouse bodyweight following intranasal administration of bleomycin. (B) Area-under-the-curve (AUC) of relative mouse bodyweight up to day 10. (C) Pulmonary histology 3 days after treatment with vehicle (left) and bleomycin (11.25 units/kg, right). Macrophage infiltrates are annotated with open arrows and lymphocyte aggregates with filled arrows. Haematoxylin and eosin stain, scale bars: 200 μm. (D) Flow cytometric analysis of macrophages in mouse lung at day 3 following bleomycin treatment (11.25 units/kg). (E) Mice with day 3 relative bodyweight AUC ≤2.92 were selected for inclusion in efficacy studies. The corresponding relative bodyweights of excluded and included (randomised) mice are presented as an example. (F) Bodyweights of control mice treated with intranasal
PBS then subjected to 1.0 Gy whole lung irradiation 24 hours later. Groups compared by Kruskal Wallis and *post hoc* Wilcoxon pairwise test, * P<0.05, *** P<0.001.

**Figure 2A**

![Graph showing relative bodyweight over time for different groups](image)

**Figure 2B**

![Graphs showing relative bodyweight over time for different conditions](images)
Figure 2C

Log-rank
$p = 0.026$

Recovery probability

Time (days)

Number at risk

Cumulative number of events

Time (days)
Figure 2D

Survival probability

- Bleo+0Gy
- Bleo+1Gy

Log-rank
p = 0.92

Time (days)

Number at risk

<table>
<thead>
<tr>
<th></th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>30</td>
<td>33</td>
<td>33</td>
<td>33</td>
<td>33</td>
<td>33</td>
<td>31</td>
<td>27</td>
<td>25</td>
<td>25</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>30</td>
<td>33</td>
<td>33</td>
<td>33</td>
<td>33</td>
<td>33</td>
<td>31</td>
<td>27</td>
<td>25</td>
<td>25</td>
<td>24</td>
</tr>
</tbody>
</table>

Cumulative number of events

<table>
<thead>
<tr>
<th></th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>4</td>
<td>8</td>
<td>8</td>
<td>9</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>4</td>
<td>8</td>
<td>8</td>
<td>9</td>
<td>10</td>
</tr>
</tbody>
</table>
Figure 2: LDLR promotes recovery of bodyweight in a subset of bleomycin-treated mice. (A) Relative bodyweight (mean ± SEM) of bleomycin-treated mice treated with LDLR (1.0 Gy) or sham irradiation on day 3. Day-by-day comparison of sham and irradiated groups performed by t-test. (B) Relative bodyweight of individual mice; recovery defined as a return to 96, 98 or 100% of baseline bodyweight (green boxes) after day 3. (C) Kaplan-Meier analysis of recovery to 98% of baseline bodyweight; groups compared by log-rank test. (D) Kaplan-Meier analysis of mouse survival. Mice exhibiting severe weight loss were culled to comply with humane endpoint. Groups compared by log-rank test. (E) Relative bodyweight AUC values up
to day 3 (prior to LDLR), grouped according to eventual study outcome. Treatment groups compared by t-test and sub-groups compared by one-way ANOVA with post hoc Tukey test. Mice whose bodyweight returned to 98% of baseline were classified as recovered. Mice sacrificed early due to an excessive reduction in bodyweight were classified as having experienced severe weight loss. ** \(P<0.01\), *** \(P<0.001\).

Figure 3A
Figure 3: LDLR reduces severity of lung pathology in a subset of bleomycin-treated mice. (A) Histology composite scores of pulmonary macrophage infiltrates and lymphocyte aggregates at day 10. Square symbols indicate images presented in (B). Mice whose bodyweight returned to 98% of baseline were classified as recovered. Groups compared by Kruskal Wallis and post hoc Wilcoxon pairwise test, *** P<0.001. (B) Examples of pulmonary histology at day 10. Macrophage infiltrates are annotated with open arrows and lymphocyte aggregates with filled arrows. Images colour-coded for cross-referencing with square symbols in (A). Haematoxylin and eosin stain, scale bars: 200 μm.
Figure 4A

Interstitial macrophages

Number of interstitial macrophages

- Non-recovered
- Recovered

Veh+0Gy
Bleo+0Gy
Bleo+1Gy

n=13  n=20  n=23

0  400000  800000

***  **

Journal Pre-proof
Figure 4B

Alveolar macrophages

- Non-recovered
- Recovered

Number of alveolar macrophages

- Veh+0Gy
- Bleo+0Gy
- Bleo+1Gy

n=13
n=20
n=23

100000
300000
Figure 4C

CD103+ DCs

- • Non-recovered
- ○ Recovered

Number of CD103+ DCs

$\text{Veh+0Gy}$  $\text{Bleo+0Gy}$  $\text{Bleo+1Gy}$

$n=13$  $n=20$  $n=23$

$^*$$^*$$^*$$^*$

$^*$$^*$$^*$

$^*$$^*$$^*$

$^*$$^*$$^*$
Figure 4: LDLR suppresses bleomycin-induced changes in immune cell numbers in mouse lung. Flow cytometric analysis of interstitial macrophages (A), alveolar macrophages (B), CD103+ dendritic cells (C) and Ly6G+ neutrophil-dendritic cell hybrids (D) in mouse lung at day 10 after bleomycin treatment. Mice whose bodyweight returned to 98% of baseline were classified as recovered. Groups compared by Kruskal Wallis and post hoc Wilcoxon pairwise test, * P<0.05, ** P<0.01, *** P<0.001.
Figure 5A

[Diagram showing raw CT images, 2D segmentations, and 3D renderings of tissue with labels for "Bleomycin + 1Gy" and "Bleomycin + 0Gy". The images are color-coded with "Poorly-vascularized" and "Normo-vascularized" annotations.]
Figure 5B

Bleomycin-treated, day 3

Aerated volume (%)

Left

Right

Lung

n=41

n=41

Figure 5C

Left lung

Blec+0Gy

P=0.0048

n=19

Blec+1Gy

P=2e-04

n=22

Right lung

Blec+0Gy

P=3e-04

n=30

Blec+1Gy

P=0.1042

n=29

Aerated volume (%)
Figure 5: LDLR protects against bleomycin-induced radiological changes in the right mouse lung. (A) The aerated volume of mouse lung was calculated from reconstructed CT images. (B) Aerated volume percentage of each lung in all bleomycin-treated mice at day 3, prior to LDLR. Groups compared by t-test. (C) Percentage aerated volume of each lung on day 3 and day 10. The presence of a consistent trend between time points was assessed by paired t-test. (D) Change in aerated volume percentage between day 10 and day 3 (day 10 – day 3) for each lung. Groups compared by t-test. * P<0.05, *** P<0.001.

Figure 6A
Figure 6B
Figure 6: LDLR using 0.5 Gy or 1.5 Gy failed to improve outcomes of bleomycin-treated mice. (A) Relative bodyweight (mean ± SEM) of bleomycin-treated mice following LDLR (0.5 Gy or 1.5 Gy) on day 3 (left panel). Kaplan-Meier analysis of recovery to 98% of baseline bodyweight (middle panel) and overall survival (right panel). Groups compared by log-rank test. (B) Flow cytometric analysis of immune cells in mouse lung at day 10. Groups compared by Kruskal Wallis and post hoc Wilcoxon pairwise test. (C) Change in aerated lung volume percentage between day 10 and day 3, determined from serial CT imaging (day 10 – day 3) for each lung. Groups compared by one-way ANOVA. * P<0.05, ** P<0.01, *** P<0.001.